🎁 Black Friday: up to 50% off of annual plans
Glenmark Pharmaceuticals Limited (BOM:532296)
India flag India · Delayed Price · Currency is INR
2,648.00
+27.00 (1.03%)
At close: Nov 20, 2026

Glenmark Pharmaceuticals Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Revenue
160,082169,825133,217118,131115,832123,049
Other Revenue
-110.75601.18415.548,323723.29-
159,971170,426133,633126,454116,556123,049
Revenue Growth
0.00%27.53%5.68%8.49%-5.28%12.44%
Cost of Revenue
52,11149,39945,25045,78944,10845,481
Gross Profit
107,860121,02788,38380,66572,44877,568
Selling, General & Admin
44,52643,39336,81434,46531,83329,176
Other Operating Expenses
29,72331,30927,63925,92423,54125,124
Operating Expenses
80,80980,43769,31466,20861,06659,168
Operating Income
27,05140,59119,06914,45711,38218,400
Interest Expense
-2,018-2,087-2,071-5,160-3,490-2,981
Interest & Investment Income
413.36413.36439.4161.7873.5297.85
Currency Exchange Gain (Loss)
3,5923,592282.27-2,035880.54
Other Non Operating Income (Expenses)
-1,588----688.35
EBT Excluding Unusual Items
27,45142,50817,7209,35910,00017,086
Gain (Loss) on Sale of Assets
---15.357.25-64.64
Legal Settlements
-----8,011-
Other Unusual Items
-8,416-22,661-3,728-9,010351.99-2,609
Pretax Income
19,03419,84713,992364.952,39814,412
Income Tax Expense
4,5226,2283,52118,6733,2944,476
Earnings From Continuing Operations
14,51213,62010,471-18,309-895.619,936
Earnings From Discontinued Operations
---3,9734,670-
Net Income to Company
14,51213,62010,471-14,3353,7749,936
Minority Interest in Earnings
1.29-1.01-0.45-681.46-801.55-519.38
Net Income
14,51313,61910,471-15,0172,9729,417
Net Income to Common
14,51313,61910,471-15,0172,9729,417
Net Income Growth
43.72%30.06%---68.44%-2.92%
Shares Outstanding (Basic)
282282282282282282
Shares Outstanding (Diluted)
282282282282282282
Shares Change
0.01%0.03%0.01%0.00%--
EPS (Basic)
51.4348.2637.11-53.2210.5333.37
EPS (Diluted)
51.4148.2437.11-53.2210.5333.37
EPS Growth
43.68%30.00%---68.43%-2.93%

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-8,26520,873-15,783-11,638176.293,185
Free Cash Flow Per Share
-29.2873.94-55.93-41.240.6311.29
Dividend Per Share
2.5005.0002.5002.5002.5002.500
Dividend Growth
-100.00%0%0%0%0%
Gross Margin
67.42%71.02%66.14%63.79%62.16%63.04%
Operating Margin
16.91%23.82%14.27%11.43%9.77%14.95%
Profit Margin
9.07%7.99%7.84%-11.88%2.55%7.65%
Free Cash Flow Margin
-5.17%12.25%-11.81%-9.20%0.15%2.59%
EBITDA
32,08644,80122,63918,29714,28919,124
EBITDA Margin
20.06%26.29%16.94%14.47%12.26%15.54%
D&A For EBITDA
5,0354,2103,5703,8402,907723.93
EBIT
27,05140,59119,06914,45711,38218,400
EBIT Margin
16.91%23.82%14.27%11.43%9.77%14.95%
Effective Tax Rate
23.76%31.38%25.16%5116.72%137.34%31.06%
Revenue as Reported
162,389174,431134,355126,531118,721124,716
Advertising Expenses
-6,9456,0795,1575,2704,349